{"url_path":"/sec/gctk/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-023205-index.html","accession_number":"0001493152-26-023205","cik":"0001506983","ticker":"GCTK","issuer_name":"Glucotrack, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-023205-index.html","primary_entity_key":"0001506983","primary_entity_name":"Glucotrack, Inc."},"word_count":1343,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001506983\n\n0001506983\n\n2026-01-01\n2026-03-31\n\n0001506983\n\n2026-05-14\n\n0001506983\n\n2026-03-31\n\n0001506983\n\n2025-12-31\n\n0001506983\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2025-12-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-12-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2024-12-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-12-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001506983\n\n2024-12-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2026-03-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-03-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001506983\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001506983\n\nGCTK:ReceiptsOnAccountOfSharesMember\n\n2025-03-31\n\n0001506983\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-03-31\n\n0001506983\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001506983\n\n2025-03-31\n\n0001506983\n\n2025-02-03\n2025-02-03\n\n0001506983\n\n2025-01-02\n\n0001506983\n\n2025-01-03\n\n0001506983\n\n2025-02-02\n\n0001506983\n\n2025-02-03\n\n0001506983\n\n2025-06-13\n2025-06-13\n\n0001506983\n\nGCTK:CommonStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nGCTK:CommonStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nGCTK:SharesIssuableUponConversionOfWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nGCTK:SharesIssuableUponConversionOfWarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001506983\n\nGCTK:NotePurchaseAgreementMember\nGCTK:PromissoryNoteMember\n\n2025-09-12\n\n0001506983\n\nGCTK:NotePurchaseAgreementMember\nGCTK:PromissoryNoteMember\n\n2025-09-12\n2025-09-12\n\n0001506983\n\nGCTK:NotePurchaseAgreementMember\nGCTK:PromissoryNoteMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nGCTK:NotePurchaseAgreementMember\nGCTK:PromissoryNoteMember\n\n2026-03-31\n\n0001506983\n\nus-gaap:CommonStockMember\n\n2025-09-11\n2025-09-11\n\n0001506983\n\n2025-09-11\n2025-09-11\n\n0001506983\n\nGCTK:SalesAgreementMember\n\n2026-03-27\n2026-03-27\n\n0001506983\n\nGCTK:SalesAgreementMember\n\n2026-03-27\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\nGCTK:PrefundedWarrantsMember\n\n2025-12-29\n2025-12-31\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\nus-gaap:CommonStockMember\n\n2025-12-29\n2025-12-31\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\nGCTK:CommonWarrantsMember\n\n2025-12-29\n2025-12-31\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\nGCTK:PrefundedWarrantsMember\n\n2025-12-31\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\nGCTK:PrefundedWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001506983\n\nGCTK:SalesAgreementMember\nsrt:MaximumMember\n\n2024-12-17\n2024-12-17\n\n0001506983\n\nGCTK:SalesAgreementMember\n\n2025-03-21\n2025-03-21\n\n0001506983\n\nGCTK:SalesAgreementMember\n\n2025-03-21\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\n\n2025-02-04\n2025-02-04\n\n0001506983\n\nGCTK:SecuritiesPurchaseAgreementMember\n\n2025-02-04\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2024-11-12\n2024-11-12\n\n0001506983\n\nGCTK:SeriesBWarrantsMember\n\n2024-11-12\n2024-11-12\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2025-01-02\n2025-01-02\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2025-01-03\n2025-01-03\n\n0001506983\n\nus-gaap:WarrantMember\n\n2025-01-03\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2024-12-31\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2024-12-31\n2024-12-31\n\n0001506983\n\nGCTK:SeriesBWarrantsMember\n\n2024-12-31\n\n0001506983\n\nGCTK:SeriesBWarrantsMember\n\n2024-12-31\n2024-12-31\n\n0001506983\n\nGCTK:SeriesBWarrantsMember\n\n2025-03-31\n\n0001506983\n\nGCTK:SeriesBWarrantsMember\n\n2025-03-31\n\n0001506983\n\nGCTK:SeriesAWarrantsMember\n\n2025-03-31\n\n0001506983\n\nGCTK:IsraeliInnovationAuthorityMember\n\n2004-03-04\n\n0001506983\n\nGCTK:IsraeliInnovationAuthorityMember\nsrt:MinimumMember\n\n2004-03-03\n2004-03-04\n\n0001506983\n\nGCTK:IsraeliInnovationAuthorityMember\nsrt:MaximumMember\n\n2004-03-03\n2004-03-04\n\n0001506983\n\nGCTK:IsraeliInnovationAuthorityMember\n\n2004-03-04\n\n0001506983\n\nGCTK:IsraeliInnovationAuthorityMember\n\n2026-03-31\n\n0001506983\n\nGCTK:IntellectualPropertyPurchaseAgreementMember\nus-gaap:CommonStockMember\n\n2022-10-07\n2022-10-07\n\n0001506983\n\nGCTK:IntellectualPropertyPurchaseAgreementMember\nus-gaap:CommonStockMember\nsrt:MinimumMember\n\n2022-10-07\n\n0001506983\n\nus-gaap:SubsequentEventMember\n\n2026-04-01\n2026-04-01\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:EquityLineOfCreditMember\n\n2026-04-01\n2026-04-01\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:EquityLineOfCreditMember\n\n2026-04-01\n2026-04-30\n\n0001506983\n\nus-gaap:SubsequentEventMember\n\n2026-04-01\n2026-04-30\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:EquityLineOfCreditMember\n\n2026-05-01\n2026-05-31\n\n0001506983\n\nus-gaap:SubsequentEventMember\n\n2026-05-01\n2026-05-31\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:FirstExchangeAgreementMember\n\n2026-04-13\n2026-04-13\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:FirstExchangeAgreementMember\nGCTK:FirstPartitionedNoteMember\n\n2026-04-13\n2026-04-13\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:SecondExchangeAgreementMember\n\n2026-04-29\n2026-04-29\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:FirstExchangeAgreementMember\n\n2026-04-29\n2026-04-29\n\n0001506983\n\nus-gaap:SubsequentEventMember\nGCTK:SecondExchangeAgreementMember\nGCTK:SecondPartitionedNoteMember\n\n2026-04-29\n2026-04-29\n\n0001506983\n\nus-gaap:SubsequentEventMember\n\n2026-04-01\n\n0001506983\n\nus-gaap:CommonStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-01\n2026-04-01\n\n0001506983\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\n\n2026-05-11\n\n0001506983\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\n\n2026-05-11\n2026-05-11\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\niso4217:ILS\n\nGCTK:Segment\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n \n\n \nFor\nthe quarterly period ended March 31, 2026\n\n \n\nor\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n \n\n \nFor\nthe transition period from ________________ to ________________\n\n \n\nCommission\nFile Number: 001-41141\n\n \n\n**GLUCOTRACK,\nINC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\nDelaware\n \n98-0668934\n\n(State\nor other jurisdiction of\n\nincorporation\nor organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n \n \n\n301\nRoute 17 North, Suite 800\n\nRutherford,\nNJ\n\n \n07070\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\n(201)\n842-7715\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nN/A\n\n(Former\nname, former address and former fiscal year, if changed since last report)\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\n**Common\nStock**\n \nGCTK\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data\nFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding\n12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,\nor an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller\nreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n \nLarge\naccelerated filer ☐\n \nAccelerated\nfiler ☐\n\n \nNon-accelerated\nfiler ☒\n \nSmaller\nreporting company ☒\n\n \nEmerging\ngrowth company ☐\n \n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 14, 2026, 6,259,279 shares of the Company’s common stock, par value $0.001 per share, were outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**GLUCOTRACK\nINC.**\n\n \n\n**TABLE\nOF CONTENTS**\n\n \n\n \n**Page**\n\n[PART I - FINANCIAL INFORMATION](#a_001)\n4\n\n[Item 1. Financial Statements.](#a_002)\n4\n\n[Condensed Consolidated Balance Sheets](#a_003)\n4\n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss](#a_004)\n5\n\n[Condensed Consolidated Statement of Changes in Stockholders’ Equity](#a_005)\n6\n\n[Condensed Consolidated Statements of Cash Flows](#a_006)\n7\n\n[Notes to Condensed Consolidated Financial Statements](#a_007)\n8\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.](#a_008)\n18\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk.](#a_009)\n22\n\n[Item 4. Controls and Procedures.](#a_010)\n22\n\n[PART II - OTHER INFORMATION](#a_011)\n23\n\n[Item 1. Legal Proceedings](#a_012)\n23\n\n[Item 1A Risk Factors](#a_013)\n23\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#a_014)\n24\n\n[Item 3. Defaults Upon Senior Securities](#a_015)\n24\n\n[Item 4. Mine Safety Disclosures](#a_016)\n24\n\n[Item 5. Other Information](#a_017)\n24\n\n[Item 6. Exhibits.](#a_018)\n25\n\n[EXHIBIT INDEX](#a_018)\n25\n\n[SIGNATURES](#a_019)\n26\n\n \n\n2\n\n \n\n \n\n**CAUTIONARY\nNOTE REGARDING FORWARD LOOKING STATEMENTS**\n\n \n\nThis\nQuarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements about our expectations,\nbeliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or\nprospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements\nregarding our future activities, events or developments, including such things as future revenues, product development, clinical trials,\nregulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business\nstrategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans,\nreferences to future success, projected performance and trends, and other such matters, are forward-looking statements. The words “believe,”\n“expect,” “intend,” “anticipate,” “estimate,” “plan,” “may,”\n“will,” “could,” “would,” “should” and other similar words and phrases or the negative\nof such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form\n10-Q are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe\nare appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake\nno obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise,\nexcept as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary\nstatements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized,\nthat they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform\nto our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially.\nRisks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified in our Annual Report\non Form 10-K for year ended December 31, 2025, under the caption “Risk Factors.” We undertake no obligation to publicly update\nor revise any forward-looking statements to reflect events or circumstances that may arise after the date of this report unless required\nby law.\n\n \n\n3\n\n \n\n \n\n**GLUCOTRACK\nINC.**\n\n**PART\nI - FINANCIAL INFORMATION**"}